Zhejiang Tailin Bioengineering Co Ltd (300813) - Net Assets
Based on the latest financial reports, Zhejiang Tailin Bioengineering Co Ltd (300813) has net assets worth CN¥806.45 Million CNY (≈ $118.01 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥946.91 Million ≈ $138.56 Million USD) and total liabilities (CN¥140.46 Million ≈ $20.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300813 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥806.45 Million |
| % of Total Assets | 85.17% |
| Annual Growth Rate | 23.34% |
| 5-Year Change | 61.71% |
| 10-Year Change | 591.53% |
| Growth Volatility | 29.89 |
Zhejiang Tailin Bioengineering Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Zhejiang Tailin Bioengineering Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Zhejiang Tailin Bioengineering Co Ltd market cap and net worth.
Annual Net Assets for Zhejiang Tailin Bioengineering Co Ltd (2013–2025)
The table below shows the annual net assets of Zhejiang Tailin Bioengineering Co Ltd from 2013 to 2025. Also explore Zhejiang Tailin Bioengineering Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥804.29 Million ≈ $117.69 Million |
-2.00% |
| 2024-12-31 | CN¥820.73 Million ≈ $120.10 Million |
+26.22% |
| 2023-12-31 | CN¥650.24 Million ≈ $95.15 Million |
+0.43% |
| 2022-12-31 | CN¥647.45 Million ≈ $94.74 Million |
+30.17% |
| 2021-12-31 | CN¥497.38 Million ≈ $72.78 Million |
+11.96% |
| 2020-12-31 | CN¥444.24 Million ≈ $65.01 Million |
+93.90% |
| 2019-12-31 | CN¥229.11 Million ≈ $33.53 Million |
+17.67% |
| 2018-12-31 | CN¥194.70 Million ≈ $28.49 Million |
+32.91% |
| 2017-12-31 | CN¥146.48 Million ≈ $21.44 Million |
+25.95% |
| 2016-12-31 | CN¥116.31 Million ≈ $17.02 Million |
+19.38% |
| 2015-12-31 | CN¥97.42 Million ≈ $14.26 Million |
+77.02% |
| 2014-12-31 | CN¥55.04 Million ≈ $8.05 Million |
-15.22% |
| 2013-12-31 | CN¥64.92 Million ≈ $9.50 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Tailin Bioengineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 393.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥242.96 Million | 30.21% |
| Common Stock | CN¥121.20 Million | 15.07% |
| Other Comprehensive Income | CN¥27.63 Million | 3.44% |
| Other Components | CN¥412.50 Million | 51.29% |
| Total Equity | CN¥804.29 Million | 100.00% |
Zhejiang Tailin Bioengineering Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Tailin Bioengineering Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jinhong Fashion Group Co Ltd
SHG:603518
|
$385.59 Million |
|
Shanghai Hi-Road Food Technology Co. Ltd.
SHE:300915
|
$385.59 Million |
|
Ashiana Housing Limited
NSE:ASHIANA
|
$385.66 Million |
|
Jinling Hotel Corp Ltd
SHG:601007
|
$385.79 Million |
|
Maha Energy AB (publ)
ST:MAHA-A
|
$385.54 Million |
|
Sichuan Huiyuan Optical Com
SHE:000586
|
$385.53 Million |
|
Komipharm International Co. Ltd
KQ:041960
|
$385.51 Million |
|
Jerusalem
TA:JBNK
|
$385.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Tailin Bioengineering Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 820,050,345 to 804,291,427, a change of -15,758,918 (-1.9%).
- Net income of 16,485,445 contributed positively to equity growth.
- Dividend payments of 24,239,843 reduced retained earnings.
- Other comprehensive income increased equity by 27,628,568.
- Other factors decreased equity by 35,633,088.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥16.49 Million | +2.05% |
| Dividends Paid | CN¥24.24 Million | -3.01% |
| Other Comprehensive Income | CN¥27.63 Million | +3.44% |
| Other Changes | CN¥-35.63 Million | -4.43% |
| Total Change | CN¥- | -1.92% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Tailin Bioengineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.63x to 3.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥2.85 | CN¥21.74 | x |
| 2014-12-31 | CN¥3.01 | CN¥21.74 | x |
| 2015-12-31 | CN¥2.73 | CN¥21.74 | x |
| 2016-12-31 | CN¥1.43 | CN¥21.74 | x |
| 2017-12-31 | CN¥1.81 | CN¥21.74 | x |
| 2018-12-31 | CN¥2.41 | CN¥21.74 | x |
| 2019-12-31 | CN¥2.82 | CN¥21.74 | x |
| 2020-12-31 | CN¥4.19 | CN¥21.74 | x |
| 2021-12-31 | CN¥4.58 | CN¥21.74 | x |
| 2022-12-31 | CN¥5.77 | CN¥21.74 | x |
| 2023-12-31 | CN¥5.61 | CN¥21.74 | x |
| 2024-12-31 | CN¥7.54 | CN¥21.74 | x |
| 2025-12-31 | CN¥6.64 | CN¥21.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Tailin Bioengineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.93%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.19x
- Recent ROE (2.05%) is below the historical average (15.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 33.05% | 22.71% | 1.15x | 1.26x | CN¥14.97 Million |
| 2014 | 18.39% | 17.01% | 0.76x | 1.42x | CN¥4.62 Million |
| 2015 | 15.78% | 18.67% | 0.63x | 1.35x | CN¥5.63 Million |
| 2016 | 24.95% | 25.96% | 0.72x | 1.34x | CN¥17.39 Million |
| 2017 | 30.71% | 31.68% | 0.73x | 1.32x | CN¥30.34 Million |
| 2018 | 24.76% | 30.31% | 0.62x | 1.31x | CN¥28.74 Million |
| 2019 | 15.02% | 19.02% | 0.68x | 1.17x | CN¥11.50 Million |
| 2020 | 10.89% | 24.16% | 0.37x | 1.22x | CN¥3.96 Million |
| 2021 | 12.77% | 22.43% | 0.43x | 1.32x | CN¥13.79 Million |
| 2022 | 12.31% | 21.31% | 0.41x | 1.43x | CN¥14.94 Million |
| 2023 | 3.03% | 7.29% | 0.28x | 1.50x | CN¥-45.21 Million |
| 2024 | 1.59% | 3.74% | 0.36x | 1.17x | CN¥-68.95 Million |
| 2025 | 2.05% | 4.93% | 0.35x | 1.19x | CN¥-63.94 Million |
Industry Comparison
This section compares Zhejiang Tailin Bioengineering Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,931,992,553
- Average return on equity (ROE) among peers: 10.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Tailin Bioengineering Co Ltd (300813) | CN¥806.45 Million | 33.05% | 0.17x | $385.56 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $931.34 Million | 24.19% | 0.17x | $422.24 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $405.69 Million | 15.24% | 0.11x | $3.84 Billion |
| Double Medical Technology Inc (002901) | $3.69 Billion | 16.27% | 0.34x | $2.35 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $615.62 Million | 6.75% | 0.04x | $520.92 Million |
| Lepu Medical Tech Beijing (300003) | $5.34 Billion | 9.76% | 0.45x | $3.09 Billion |
| INKON Life Technology Co Ltd (300143) | $2.24 Billion | 5.72% | 0.18x | $797.29 Million |
| Edan Instruments Inc (300206) | $1.18 Billion | 2.94% | 0.08x | $968.68 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $354.32 Million | 9.53% | 0.12x | $609.04 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.43 Billion | 5.13% | 0.23x | $460.12 Million |
| Sinocare Inc (300298) | $3.14 Billion | 14.20% | 0.47x | $1.28 Billion |
About Zhejiang Tailin Bioengineering Co Ltd
Zhejiang Tailin BioEngineering Co.,Ltd engages in the research and development, production, and sale of microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally. The company primarily offers aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technolog… Read more